169 related articles for article (PubMed ID: 35784467)
1. Chemotherapy- and Immune-Related Gene Panel in Prognosis Prediction and Immune Microenvironment of SCLC.
Chen MY; Zeng YC; Zhao XH
Front Cell Dev Biol; 2022; 10():893490. PubMed ID: 35784467
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer.
Song Y; Sun Y; Sun T; Tang R
Comb Chem High Throughput Screen; 2020; 23(5):381-391. PubMed ID: 32264809
[TBL] [Abstract][Full Text] [Related]
3. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
Chen P; Zhao L; Wang H; Zhang L; Zhang W; Zhu J; Yu J; Zhao S; Li W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362829
[TBL] [Abstract][Full Text] [Related]
4. Exploring effective biomarkers and potential immune related gene in small cell lung cancer.
Yunchu Y; Miyanaga A; Matsuda K; Kamio K; Seike M
Sci Rep; 2024 Mar; 14(1):7604. PubMed ID: 38556560
[TBL] [Abstract][Full Text] [Related]
5. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the DNA polymerase binding pathway affect the immune microenvironment of patients with small-cell lung cancer and enhance the efficacy of platinum-based chemotherapy.
Lin A; Mou W; Zhu L; Yang T; Zhou C; Zhang J; Luo P
Cancer Innov; 2023 Dec; 2(6):500-512. PubMed ID: 38125769
[TBL] [Abstract][Full Text] [Related]
7. Activation of the TGF-
Lin A; Zhu L; Jiang A; Mou W; Zhang J; Luo P
Dis Markers; 2022; 2022():8766448. PubMed ID: 36590751
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100.
Xiao F; Bai Y; Chen Z; Li Y; Luo L; Huang J; Yang J; Liao H; Guo L
Eur J Cancer; 2014 May; 50(8):1541-54. PubMed ID: 24559685
[TBL] [Abstract][Full Text] [Related]
9. CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer.
Tang Y; Hu Y; Niu Y; Sun L; Guo L
Front Med (Lausanne); 2022; 9():834725. PubMed ID: 35252266
[TBL] [Abstract][Full Text] [Related]
10. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
11. GBP5 Expression Predicted Prognosis of Immune Checkpoint Inhibitors in Small Cell Lung Cancer and Correlated with Tumor Immune Microenvironment.
Tong Q; Li D; Yin Y; Cheng L; Ouyang S
J Inflamm Res; 2023; 16():4153-4164. PubMed ID: 37750170
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential target genes and crucial pathways in small cell lung cancer based on bioinformatic strategy and human samples.
Chen X; Wang L; Su X; Luo SY; Tang X; Huang Y
PLoS One; 2020; 15(11):e0242194. PubMed ID: 33186389
[TBL] [Abstract][Full Text] [Related]
13. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
[TBL] [Abstract][Full Text] [Related]
14. m
Zhang Z; Zhang C; Luo Y; Wu P; Zhang G; Zeng Q; Wang L; Yang Z; Xue L; Zheng B; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
BMC Med; 2021 Nov; 19(1):284. PubMed ID: 34802443
[TBL] [Abstract][Full Text] [Related]
15. Nucleic acid-sensing-related gene signature in predicting prognosis and treatment efficiency of small cell lung cancer patients.
Liu Q; Li Z; Li N; Liu J; Wu H; Chen J
Front Oncol; 2024; 14():1394286. PubMed ID: 38680855
[TBL] [Abstract][Full Text] [Related]
16. Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-Resistance.
Kim J; Kim S; Park SY; Lee GK; Lim KY; Kim JY; Hwang JA; Yu N; Kang EH; Hwang M; Song BR; Park C; Han JY
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509231
[TBL] [Abstract][Full Text] [Related]
17. The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in
Wang Z; Zhang L; Xu W; Li J; Liu Y; Zeng X; Zhong M; Zhu Y
J Inflamm Res; 2022; 15():649-667. PubMed ID: 35140497
[TBL] [Abstract][Full Text] [Related]
18. DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer.
Dai J; Jiang M; He K; Wang H; Chen P; Guo H; Zhao W; Lu H; He Y; Zhou C
Front Oncol; 2021; 11():708294. PubMed ID: 34604048
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.
Chen P; Wang H; Zhao L; Guo H; Zhang L; Zhang W; Sun C; Zhao S; Li W; Zhu J; Yu J; Wu C; He Y
Front Oncol; 2021; 11():713853. PubMed ID: 34900670
[TBL] [Abstract][Full Text] [Related]
20. Common and distinct features of potentially predictive biomarkers in small cell lung carcinoma and large cell neuroendocrine carcinoma of the lung by systematic and integrated analysis.
Dong S; Liang J; Zhai W; Yu Z
Mol Genet Genomic Med; 2020 Mar; 8(3):e1126. PubMed ID: 31981472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
